No abstract available.
Jurisprudence*

Centric Relation ; Humans ; Jaw ; Joints ; Mouth ; Splints ; Temporomandibular Joint Disorders ; Temporomandibular Joint

BACKGROUND: Recently Malassezia (M.) furfur fungemia has been increasingly recognized in premature infants and adults receiving parenteral nutrition. Accordingly, analysis of nucleic acids in M. furfur serovars and strain typing methods based on genetic differences and similarities are required for epidemiological studies. OBJECTIVE: This study was done to analyze nucleic acids in M. furfur serovars A, B and C and to adapt the method of restriction fragment length polymorphism (RFLP) analysis of DNA to differentiate the strains of M. furfur serovars for use in epidemiological studies. METHODS: Cellular nucleic acids were extracted from the strains of M. furfur serovars and electrophoresed, followed by digestion of DNA and electrophoresis of the resultant DNA fragmegments. RESULTS: Each of the six strains, grown both on solid medium and liquid medium, revealed a genomic DNA. Interestingly, unique extra bands of RNA were observed in four of the six strains which had grown on solid medium. These bands were also seen in three of them grown in broth. The size of these bands were from 0.5 to 5.0 kbp by comparison with a ‘1 kb DNA ladder’. The restriction patterns generated by EcoR I, Hae III, Hind III, and Hinf I were not unsuccessful. The DNA from serovar B was insensitive to the above restriction enzymes. CONCLUSIONS: Although DNA was extracted from the strains, the amounts were not thought to be enough for RFLP analysis and the DNA from the serovar B was insensitive to the above restriction enzymes. Thus, further development of an extraction method of DNA is required for obtaining enough DNA from M. furfur serovars, and other restriction enzymes would have to be investigated for their ability to differentiate strains of M. furfur in epidemiological studies. Also, further investigation of RNA bands might be able to adapt them for a typing method.
Adult ; Digestion ; DNA ; Electrophoresis ; Epidemiologic Studies ; Fungemia ; Humans ; Infant, Newborn ; Infant, Premature ; Malassezia* ; Methods ; Nucleic Acids* ; Parenteral Nutrition ; Polymorphism, Restriction Fragment Length ; RNA ; Serogroup*

No abstract available.
Animals ; Femoral Artery ; Rats

BACKGROUND: Therapeutic drug monitoring (TDM) has been shown to be effective in minimizing the risk for toxicity and maximizing the efficacy of the drugs. The application of pharmacokinetics principles to indiviualization and optimization of dosage is necessary. We evolved interpretative report system of digoxin determination in a view of individual's pharmacokinetics. The alto of the present study is to validate the effectiveness of the interpretative report system in digoxin therapeutic monitoring service. METHODS: We reviewed 125 inpatients of two groups. 4 group, before interpretative reporting, had 86 inpatients from February 1996 to March 1996. B group included 39 inpatients from September 1996 to October 1996 after the practice of the sytem. Digoxin concentrations were measured in serum by TDxFlex (Abbott Laboratories, U.S.A.). Each patient's digoxin pharmacokinetics was determined by using the Abbott-base Pharmacokinetics system (Abbott Laboratories, U.S.A.) . The interpretation for the assayed digoxin level, the recommendation of maintenance dosage and the simulation graph with predicted serum levels were included in the report. The effectiveness of the reporting system was evaluated by comparing the appropriateness of digoxin level measurement between both groups. RESULTS: It revealed that appropriate measurements of digoxin level were 59.5 % of the tests in A group and 77.1% of those in B group (p=0.006). Evaluation of serum digoxin concentrations stratified by digoxin concentration showed also significant difference among the percentage of tests in each concentration range between both groups (p=0.011). CONCLUSIONS: Interpretative report system for the assayed results caused to increase in the appropriateness of digoxin measurement. The report system with some improvement which is achieved through the active approach to physician helps us use TDM effectively. The system can be applied to the other TDM drugs.
Digoxin ; Drug Monitoring* ; Humans ; Inpatients ; Pharmacokinetics

BACKGROUND: Therapeutic drug monitoring (TDM) has been shown to be effective in minimizing the risk for toxicity and maximizing the efficacy of the drugs. The application of pharmacokinetics principles to indiviualization and optimization of dosage is necessary. We evolved interpretative report system of digoxin determination in a view of individual's pharmacokinetics. The alto of the present study is to validate the effectiveness of the interpretative report system in digoxin therapeutic monitoring service. METHODS: We reviewed 125 inpatients of two groups. 4 group, before interpretative reporting, had 86 inpatients from February 1996 to March 1996. B group included 39 inpatients from September 1996 to October 1996 after the practice of the sytem. Digoxin concentrations were measured in serum by TDxFlex (Abbott Laboratories, U.S.A.). Each patient's digoxin pharmacokinetics was determined by using the Abbott-base Pharmacokinetics system (Abbott Laboratories, U.S.A.) . The interpretation for the assayed digoxin level, the recommendation of maintenance dosage and the simulation graph with predicted serum levels were included in the report. The effectiveness of the reporting system was evaluated by comparing the appropriateness of digoxin level measurement between both groups. RESULTS: It revealed that appropriate measurements of digoxin level were 59.5 % of the tests in A group and 77.1% of those in B group (p=0.006). Evaluation of serum digoxin concentrations stratified by digoxin concentration showed also significant difference among the percentage of tests in each concentration range between both groups (p=0.011). CONCLUSIONS: Interpretative report system for the assayed results caused to increase in the appropriateness of digoxin measurement. The report system with some improvement which is achieved through the active approach to physician helps us use TDM effectively. The system can be applied to the other TDM drugs.
Digoxin ; Drug Monitoring* ; Humans ; Inpatients ; Pharmacokinetics

BACKGROUND: Methylmalonic aciduria can be caused by inherited defects in the methylmalonyl-CoA mutase enzyme, Inherited defects in the metabolism of vitamin Bl2 and acquired or inherited vitamin Bl2 deficiency. Quantitation of urinary methylmalonic acid (MMA) is very useful In diagnosis of methylmalonic acidemia and cobalamin deficiency. We evaluated a quantitation method of urinary MMA and determined reference values. METHODS: The method involved stable isotope dilution gas chromatographymass spectrometry (GC-MS) with (methyl 2H3)-MMA as the internal standard. We determined the detection limit, linearity and periodic variations of the assay. Urinary MMA levels were measured in 70 individuals of ages newborn to 58 years with no metabolic disorders. RESULTS: The lower limit of detection calculated from blank runs (mean+/-3SD) was 2.62nmo1/m1. One control urine tramp)e analyzed 23 times within 3 weeks game results of 7.83+/-1.09 (mean+/-SD, CV=13.8%) nmol/mL. The linearity at four different concentrations of MMA was acceptable (R2=0.9992). The concentration of urinary MMA in 70 individuals was 2.33+/-2.19 mmol/mol creatinine (mean+/-SD). Age related reference values which decreased with age were also reported (p=1.23x10-9). CONCLUSIONS: The described method is sensitive, specific and noninvasive, which is considered the gold standard method for measuring MMA. The method could be used as a screening test for cobalamin deficiency and inherited methyl malonic acidemia. On the basis of the narrow range of normal concentration, it is expected that the method would readily detect mild cobalamin deficiency.
Chromatography, Gas* ; Creatinine ; Diagnosis ; Gas Chromatography-Mass Spectrometry* ; Humans ; Infant, Newborn ; Limit of Detection ; Mass Screening ; Metabolism ; Methylmalonic Acid* ; Methylmalonyl-CoA Mutase ; Reference Values ; Spectrum Analysis ; Vitamin B 12 ; Vitamins

No Abstract available.

To identify the developmental characteristics of fetal skin, the expressions of cytokeratine (CK) and epidermal growth factor (EGFR) in fetal skin (12-24 weeks of gestation) were studied immunohistochemically, and the ultrastructure of epidermis was also observed. The Expressions of CK and EGFR were identified in labelled sterptoavidine biotin immunohistochemical method. Primary antibodies used monclonal mouse anti-human CK (DAKO-CK, MF116) and EGFR Ab-4 which is rabbit affinity-purified polyclonal antibody raised against the amino acid residues 1005-1016 (Onc Science). At 12 weeks of gestation the epidermis was composed basal layer and periderm and the cells of both layers were positively stained for CK and EGFR. At 16-18 weeks of gestation, epidermis was composed basal, intermediate, and periderm. The cells of basal layer and periderm were strongly positive for CK, but the cells of intermediate layer showed weak or negative reaction for CK. EGFR immunoreactivity was noted in cells of all three layers, though cells of basal layer were stained relatively weak. At 23-24 weeks of gestation, the epidermis thickened and appeared 6 or more cell layers. Epidermal cells except horny layer were stained positively for CK and EGFR. EGFR immunoreactivity in basal layer, however, was relatively weak compared to those in intermediate layers. Periderm always were reaction-positive for CK and EGFR. The hair follicles, mainly pre-germ stage, were negatively stained for CK and EGFR at 12 weeks of gestation. The hair follicles with various developing stages were positively stained at 16-18 weeks of gestation. At 24 weeks of gestation, inner sheath of hair shaft and sebaceous gland were strongly reacted for CK, but not reacted for EGFR. In electron microscopic study, epidermis was composed of two layers, basal layer and periderm at 12 weeks of gestation. The periderm was composed of basal, intermediate and periderm at 12 weeks of gestation. The periderm was composed of basal, intermediate and periderm layers at 16-18 weeks of gestation. Intermediate cells consisted of 2-3 layers of spinous cells. The granular cells appeared rarely in superficial cells of intermediate layers. At 23-24 weeks of gestation, epidermis consisted of basal, prickle, granular, and horny layers. Periderm cells were locally exfoliated from the hony layer. The results demonstrate the expression of CK and EGFR in skin of human fetus between 12 and 24 weeks of gestation, and suggest that full thickness of epidermis is formed by 24 weeks of gestation.
Animals ; Antibodies ; Biotin ; Epidermal Growth Factor ; Epidermis* ; Fetus* ; Hair ; Hair Follicle ; Humans* ; Keratins ; Methods ; Mice ; Pregnancy ; Receptor, Epidermal Growth Factor ; Sebaceous Glands ; Skin

No abstract available in English.
Methods